Evidence map›Paper›PMID 35872909›Full record

ArticleFrontiers in cardiovascular medicine2022

Impact of High-Power and Very High-Power Short-Duration Radiofrequency Ablation on Procedure Characteristics and First-Pass Isolation During Pulmonary Vein Isolation.

Zoltán Salló, Péter Perge, Bernadett Balogi, Gábor Orbán, Katalin Piros, Szilvia Herczeg, Klaudia Vivien Nagy, István Osztheimer, Pál Ábrahám, Béla Merkely and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05777551 (Atrial Fibrillation Ablation by Means of Very High Power Short Duration), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05777551 recruitingnot on this mapstarted 2023, after this paper: background citation

Atrial Fibrillation Ablation by Means of Very High Power Short Duration (AIR HPSD Registry)

Typeobservational_patient_registrySponsorClinica MediterraneaRan2023 to 2027Enrolled850ConditionsAtrial Fibrillation, Catheter Ablation
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Temperature-guided high and very high-power short duration ablation for atrial fibrillation treatment: the peQasus multicentre study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Incidence and predictors of stroke and silent cerebral embolism following very high-power short-duration atrial fibrillation ablation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Zoltán SallóHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Péter PergeHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Bernadett BalogiHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Gábor OrbánHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Katalin PirosHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Szilvia HerczegHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Klaudia Vivien NagyHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
István OsztheimerHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Pál ÁbrahámHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Béla MerkelyHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
László GellérHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Nándor SzegediHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Semmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: High-power short-duration (HPSD) radiofrequency ablation has been proposed to produce rapid and effective lesions for pulmonary vein isolation (PVI). We aimed to evaluate the procedural characteristics and the first-pass isolation (FPI) rate of HPSD and very high-power short-duration (vHPSD) ablation compared to the low-power long-duration (LPLD) ablation technique. Methods: One hundred fifty-six patients with atrial fibrillation (AF) were enrolled and assigned to LPLD, HPSD, or vHPSD PVI. The energy setting was 30, 50, and 90 W in the LPLD, HPSD, and vHPSD groups, respectively. In the vHPSD group, 90 W/4 s energy delivery was used in the QMODE+ setting. In the other groups, ablation index-guided applications were delivered with 30 W (LPLD) or 50 W (HPSD). Results: Bilateral PVI was achieved in all cases. Compared to the LPLD group, the HPSD and vHPSD groups had shorter procedure time [85 (75-101) min, 79 (65-91) min, and 70 (53-83) min], left atrial dwelling time [61 (55-70) min, 53 (41-56) min, and 45 (34-52) min], total RF time [1,567 (1,366-1,761) s, 1,398 (1,021-1,711) s, and 336 (247-386) s], but higher bilateral FPI rate (57, 78, and 80%) (all Conclusion: Our prospective, observational cohort study showed that both HPSD and vHPSD RF ablation shortens procedure and RF time and results in a higher rate of FPI compared to LPLD ablation. Moreover, the use of HPSD and vHPSD ablation increased the acute and mid-term success rate. No safety concerns were raised for HPSD or vHPSD ablation in our study.

Indexed as

ablationatrial fibrillationfirst-pass isolationhigh-power short-durationpulmonary vein isolationvery high-power short-duration

Identifiers

PMID35872909
PMCPMC9300971
OpenAlexW4284895530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.